Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy

Annals of Oncology

Volumn 23, Issue 12, 2012, Pages 3051-3057

  Tominaga, N ^a   Naoi, Y ^a   Shimazu, K ^a   Nakayama, T ^a   Maruyama, N ^a   Shimomura, A ^a   Kim, S J ^a   Tamaki, Y ^a   Noguchi, S ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; GATA3; Intrinsic subtype; Microarray; Neoadjuvant chemotherapy; Pathological complete response

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; KI 67 ANTIGEN; MUCIN 1; PACLITAXEL; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR GATA 3;

ADULT; AGED; ARTICLE; BREAST; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA MICROARRAY; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; MASTECTOMY; MUTATIONAL ANALYSIS; PREDICTION; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 84869763031     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds120     Document Type: Article

References (31)

1. Fang SH, Chen Y, Weigel RJ. GATA-3 as a marker of hormone response in breast cancer. J Surg Res 2009; 157: 290-295.
2. Yang Z, Gu L, Romeo PH et al. Human GATA-3 trans-activation, DNA-binding, and nuclear localization activities are organized into distinct structural domains. Mol Cell Biol 1994; 14: 2201-2212.
3. Asselin-Labat ML, Sutherland KD, Barker H et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 2007; 9: 201-209.
4. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 2006; 127: 1041-1055.
5. Kouros-Mehr H, Bechis SK, Slorach EM et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 2008; 13: 141-152.
6. Kouros-Mehr H, Kim JW, Bechis SK, Werb Z. GATA-3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol 2008; 20: 164-170.
7. Bernardo GM, Lozada KL, Miedler JD et al. FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development 2010; 137: 2045-2054.
8. Abba MC, Nunez MI, Colussi AG et al. GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells. Breast Cancer Res 2006; 8: R64.
9. Demir H, Turna H, Can G, Ilvan S. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression. J BUON 2010; 15: 774-782.
10. Usary J, Llaca V, Karaca G et al. Mutation of GATA3 in human breast tumors. Oncogene 2004; 23: 7669-7678.
11. Arnold JM, Choong DY, Thompson ER et al. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2-or sporadic breast tumors. Breast Cancer Res Treat 2010; 119: 491-496.
12. Yoon NK, Maresh EL, Shen D et al. Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol 2010; 41: 1794-1801.
13. Tokuda E, Seino Y, Arakawa A et al. Estrogen receptor-alpha directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2011; [epub ahead of print], doi:10.1007/s10549-10011-11758-x.
14. Ren J, Agata N, Chen D et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004; 5: 163-175.
15. Ciocca V, Daskalakis C, Ciocca RM et al. The significance of GATA3 expression in breast cancer: a 10-year follow-up study. Hum Pathol 2009; 40: 489-495.
16. Ademuyiwa FO, Thorat MA, Jain RK et al. Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Mod Pathol 2010; 23: 270-275.
17. Matsukita S, Nomoto M, Kitajima S et al. Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in mucinous carcinoma of the breast: comparison with invasive ductal carcinoma. Histopathology 2003; 42: 26-36.
18. Naoi Y, Kishi K, Tanei T et al. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers. Cancer 2011; 117: 3682-3690.
19. Muroya K, Hasegawa T, Ito Y et al. GATA3 abnormalities and the phenotypic spectrum of HDR syndrome. J Med Genet 2001; 38: 374-380.
20. Oshima K, Naoi Y, Kishi K et al. Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/ epirubicin/cyclophosphamide in human breast cancer. Cancer Lett 2011; 307: 149-157.
21. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
22. Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it!. J Cell Physiol 2010; 222: 42-49.
23. Albergaria A, Paredes J, Sousa B et al. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res 2009; 11: R40.
24. Nakshatri H, Badve S. FOXA1 in breast cancer. Expert Rev Mol Med 2009; 11: e8.
25. Badve S, Nakshatri H. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol 2009; 62: 6-12.
26. Yan W, Cao QJ, Arenas RB et al. GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem 2010; 285: 14042-14051.
27. Buron N, Guery L, Creuzot-Garcher C et al. Trefoil factor TFF1-induced protection of conjunctival cells from apoptosis at premitochondrial and postmitochondrial levels. Invest Ophthalmol Vis Sci 2008; 49: 3790-3798.
28. Vie N, Copois V, Bascoul-Mollevi C et al. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer 2008; 7: 14.
29. Brychtova V, Vojtesek B, Hrstka R. Anterior gradient 2: a novel player in tumor cell biology. Cancer Lett 2011; 304: 1-7.
30. Kastl L, Brown I, Schofield AC. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat 2011; 131: 445-454.
31. Molenaar JJ, Ebus ME, Koster J et al. Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells. Oncogene 2010; 29: 2739-2745.